logo
Products
Services
Resources
Selection Guides
About
XFD594 Anti-human CD16 Antibody
3G8
The 3G8 monoclonal antibody recognizes human CD16a, a 50 - 65 kD transmembrane protein typically found on the surface of macrophages, natural killer cells, dendritic cells, monocytes and neutrophils. CD16 is a member of key cellular pathways, namely, the Fc-gamma receptor signaling pathway involved in phagocytosis. From a research standpoint, it is of biological interest due to its association with important macromolecules/ligands like IgG Fc. CD16 is a very popular antibody target, with over 25000 publications in the last decade. CD16a is frequently used in flow cytometry applications as a phenotypic marker for differentiation of cell types, particularly in the study of immunology. This antibody was purified through affinity chromatography and conjugated to XFD594 (ex/em = 590/618 nm). XFD594 is manufactured by AAT Bioquest, and it has a chemical structure similar to that of Alexa Fluor® 594 (Alexa Fluor® is the trademark of Thermo Fisher). It is compatible with the 592 nm laser and 610/30 nm bandpass filter (for example, as in the Luminex Amnis ImageStream).
product image
CatalogSize
Price
Quantity
10161170100 tests
Price
10161171500 tests
Price
 
Physical properties

Molecular weightN/A
Solventwater
Antibody properties

Other namesFCRIIIA
Clone3G8
HostMouse
ReactivityHuman
ApplicationFlow Cytometry (FACS), Fluorescence Imaging
Spectral properties

Absorbance (nm)592
Correction factor (260 nm)0.43
Correction factor (280 nm)0.56
Extinction coefficient (cm -1 M -1)
90000
Excitation (nm)590
Emission (nm)618
Quantum yield
0.66
1
Usage and storage

Intended useResearch Use Only (RUO)
StorageRefrigerated (2-8 °C); Minimize light exposure
Contact us

Telephone
Fax
Emailsales@aatbio.com
InternationalSee distributors
Bulk requestInquire
Custom sizeInquire
Technical SupportContact us
Request quotationRequest
Purchase orderSend to sales@aatbio.com
ShippingStandard overnight for United States, inquire for international
Page updated on August 10, 2026